Nosopharm, a company dedicated to the research and development of new anti-infective drugs, and Evotec SE, a drug discovery and development company, today announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a secondgeneration Odilorhabdin drug candidate. Financial terms of the agreement were not disclosed.

Complete press release Nosopharm